Moderna, Inc. (NASDAQ:MRNA) shares are trading higher after analysts at multiple firms raised their price targets on the stock. The company has attracted investor interest recently, as it is working on a coronavirus (COVID-19) vaccine.
Morgan Stanley maintained an Overweight rating and raised its price target from $30 to $37.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Oppenheimer maintained an Outperform rating and raised its price target from $31 to $43.
Moderna shares were trading up 10.65%, hitting a 52-week high of $38.35 on Wednesday. The stock has a 52-week low of 11.54.